Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
PRIMARY OBJECTIVES: I. To estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab. SECONDARY OBJECTIVES: I. To estimate event-free survival at 18 months for the subset of patients with papillary cancer (Ta/T1). II. To estimate progression-free survival, cystectomy-free survival, bladder cancer-specific survival, overall survival in all patients. TERTIARY OBJECTIVES: I.
Start Date: February 7, 2017
Completion Date: February 28, 2020